

## **CTMO: pubblicazioni scientifiche su riviste con impact factor nel corso dell'anno 2017**

1. Martino M, Ciavarella S, De Summa S, Russo L, Meliambro N, Imbalzano L, Gallo GA, Moscato T, Messina G, Ferreri A, Cuzzola M, Irrera G, Naso V, Cimminiello M, Console G, Loseto G, Tommasi S, Guarini A. A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. *Biol Blood Marrow Transplant.* 2017 Oct 13. pii: S1083-8791(17)30764-4. doi: 10.1016/j.bbmt.2017.09.021 **(2016 Impact Factor: 4.704)**
2. Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palumbo A, Storino F, Martino M, Morabito F. Venetoclax for the treatment of chronic lymphocytic leukemia. *Expert Opin Investig Drugs.* 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173 **(2016 Impact Factor: 4.030)**
3. Martino M, Console G, Russo L, Meliado' A, Meliambro N, Moscato T, Irrera G, Messina G, Pontari A, Morabito F. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model. *Clin Lymphoma Myeloma Leuk.* 2017 Aug;17(8):506-512. doi: 10.1016/j.clml.2017.05.018 **(2016 Impact Factor: 2.494)**
4. Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation). A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. *Am J Hematol.* 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817 **(2016 Impact Factor: 5.275)**
5. Martino M, Gori M, Pitino A, Gentile M, Dattola A, Pontari A, Vigna E, Moscato T, Recchia AG, Barilla' S, Tripepi G, Morabito F. Basal CD34+ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony-Stimulating Factor: A Longitudinal, Prospective, Observational, Single-Center, Cohort Study. *Biol Blood Marrow Transplant.* 2017 Jul;23(7):1215-1220. doi: 10.1016/j.bbmt.2017.03.024. **(2016 Impact Factor: 4.704)**
6. Stellitano A, Fedele R, Barilla S, Iaria A, Rao CM, Martino M. Chemotherapy and Cardiotoxicity in Hematologic Malignancies. *Curr Cancer Drug Targets.* 2017;17(4):311-324 **(2016 Impact Factor: 2.992)**

7. Necchi A, Lo Vullo S, Bregni M, Rosti G, Mariani L, Raggi D, Giannatempo P, Secondino S, Schumacher K, Massard C, Kanfer E, Oechsle K, Laszlo D, Michieli M, Ifrah N, Mercier M, Crysandt M, Wuchter P, Nagler A, Wahlin A, Martino M, Badoglio M, Pedrazzoli P, Lanza F; European Society for Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party. Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012 Clin Genitourin Cancer. 2017 Feb;15(1):163-167. doi: 10.1016/j.clgc.2016.06.013 **(2016 Impact Factor: 2.535)**
8. Girmenia C, Bertaina A, Piciocchi A, Perruccio K, Algarotti A, Busca A, Cattaneo C, Raiola AM, Guidi S, Iori AP, Candoni A, Irrera G, Milone G, Marcacci G, Scimè R, Musso M, Cudillo L, Sica S, Castagna L, Corradini P, Marchesi F, Pastore D, Alessandrino EP, Annaloro C, Ciceri F, Santarone S, Nassi L, Farina C, Viscoli C, Rossolini GM, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO) and Associazione Microbiologi Clinici Italiani (AMCLI). Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin Infect Dis. 2017 Nov 13;65(11):1884-1896. doi: 10.1093/cid/cix690. **(2016 Impact Factor: 8.216)**
9. Rubio MT, D'Aveni-Piney M, Labopin M, Hamladji RM, Sanz MA, Blaise D, Ozdogu H, Daguindeau E, Richard C, Santarone S, Irrera G, Yakoub-Agha I, Yeshurun M, Diez-Martin JL, Mohty M, Savani BN, Nagler A. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. J Hematol Oncol. 2017 Jan 24;10(1):31. doi: 10.1186/s13045-016-0389-4 **(2016 Impact Factor: 6.350)**
10. Lorentino F, Labopin M, Fleischhauer K, Ciceri F, Mueller CR, Ruggeri A, Shimoni A, Bornhäuser M, Bacigalupo A, Gülbas Z, Koc Y, Arcese W, Bruno B, Tischer J, Blaise D, Messina G, Beelen DW, Nagler A, Mohty M. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv. 2017 Apr 21;1(11):669-680. doi: 10.1182/bloodadvances.2017006429. eCollection 2017 Apr 25

11. Ruggieri A, Sun Y, Labopin M, Bacigalupo A, Lorentino F, Arcese W, Santarone S, Gülbas Z, Blaise D, Messina G, Ghavamzadeh A, Malard F, Bruno B, Diez-Martin JL, Koc Y, Ciceri F, Mohty M, Nagler A. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. *Haematologica*. 2017 Feb;102(2):401-410. doi: 10.3324/haematol.2016.151779. **(2016 Impact Factor: 7.702)**
  
12. Cattina F, Bernardi S, Mantovani V, Toffoletti E, Santoro A, Pastore D, Martino B, Console G, Martinelli G, Malagola M. Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor. *Hematol Rep*. 2017 Sep 26;9(3):7051.